middle.news
Neurotech advances NTI164 into pivotal Phase 3 autism testing
8:22am on Wednesday 28th of October, 2026 AEDT
•
Biotechnology
Read Story
Neurotech advances NTI164 into pivotal Phase 3 autism testing
8:22am on Wednesday 28th of October, 2026 AEDT
Key Points
First patient dosed in the up-to-200-patient Beyond Harmony Phase 3 trial
All six Australian trial sites initiated across five states
FDA cleared the NTI164 Investigational New Drug submission
Approximately $4.5 million placement supported by a $3.15 million secured R&D loan
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurotech International (ASX:NTI)
OPEN ARTICLE